Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Clinical trial NCT05289687 · RECRUITING
Trial details
- NCT number
- NCT05289687
- Sponsor
- Eastern Cooperative Oncology Group
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-25
- Primary completion
- 2027-06-30
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.